ESOSDRIFT FAST

ESODRIFT FAST is a pharmacologically innovative formulation combining esomeprazole — the most bioavailable standard PPI — with sodium bicarbonate as an alkaline buffer, creating a product that simultaneously addresses the delayed onset problem inherent to all conventional PPIs.

Esomeprazole 40mg (S-isomer of omeprazole, ~89% oral bioavailability) is a second-generation PPI that irreversibly inhibits H⁺/K⁺-ATPase on the gastric parietal cell. Like all PPIs, conventional esomeprazole requires enteric coating to survive gastric acid and reach the small intestine for absorption. This enteric-coated delivery results in a 2–4 hour delay before meaningful acid suppression begins — the fundamental pharmacokinetic limitation of all standard PPI formulations.

Sodium Bicarbonate as Buffer: The inclusion of sodium bicarbonate as an immediate-release alkalising agent within the ESODRIFT FAST tablet produces an innovative dual action. On tablet disintegration in the stomach, sodium bicarbonate rapidly neutralises gastric acid (pH rises from ~1.5 to >4 within minutes), creating two simultaneous benefits: immediate symptomatic acid relief for the patient AND a transient alkaline microenvironment that protects the esomeprazole from acid degradation without requiring an enteric coating. The uncoated esomeprazole is absorbed more rapidly than enteric-coated esomeprazole, achieving effective plasma concentrations and proton pump inhibition within 30–45 minutes of dosing — significantly faster than the 2–4 hour onset of conventional enteric-coated PPIs.

This buffered, immediate-release PPI technology (similar to the commercially validated Zegerid® formulation) represents a rational pharmacological solution to the delayed onset problem — providing both immediate symptomatic acid neutralisation (sodium bicarbonate) and sustained 24-hour acid suppression (esomeprazole) from a single uncoated tablet.

ESODRIFT FAST is specifically indicated for clinical situations requiring rapid onset of acid suppression alongside sustained acid control — the primary advantage over conventional enteric-coated PPIs.

Erosive Oesophagitis (Primary): GORD with oesophageal erosions — the faster onset provides earlier mucosal protection during the healing phase, and the higher esomeprazole bioavailability (~89% versus ~35% for omeprazole) achieves more potent acid suppression for accelerated healing.

Acute Heartburn with GORD: On-demand use for breakthrough heartburn in GORD patients where faster acid relief than standard PPI therapy can provide is needed. The sodium bicarbonate component provides within-minutes relief while esomeprazole establishes 24-hour sustained suppression.

H. pylori Eradication: The higher intragastric pH achieved by ESODRIFT FAST from the first dose is pharmacologically important for H. pylori eradication — optimal antibiotic activity against H. pylori requires sustained pH >5, and faster PPI onset improves this condition from the first dose of the 14-day course.

Pre-Operative Aspiration Prophylaxis: Rapid pH elevation in surgical patients at risk of aspiration pneumonia — faster onset than conventional PPI formulations is clinically important in the peri-operative context.

Zollinger-Ellison Syndrome: High-volume acid hypersecretion requiring rapid and sustained maximum acid suppression.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.